Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will make an assessment of the accessibility of treatment for terminal lung condition idiopathic pulmonary fibrosis on the NHS.

NHS England is committed to improving outcomes for people with respiratory conditions, particularly through early and accurate diagnosis, which is a priority area under the NHS Long Term Plan.

A key component of an early and accurate diagnosis for a number of respiratory conditions, including pulmonary fibrosis, is the provision of quality assured spirometry. Additional funding has been made available to systems in 2021/22, 2022/23, 2023/24 and 2024/25.

NHS England has worked with a range of partners, including Asthma and Lung UK, the British Thoracic Society, the Association for Respiratory Technology and Physiology, and clinical network leads, to develop a package for systems containing the information and support required to help increase the number of people receiving early and accurate diagnosis for respiratory disease.​

NHS England is investing in additional diagnostic capacity for respiratory pathways as part of the £2.3 billion 2021 Spending Review capital investment in diagnostics. Community Diagnostic Centres are being established to deliver additional, digitally connected diagnostic capacity in England, providing patients with a coordinated set of diagnostic tests in the community, in as few visits as possible, enabling an accurate and fast diagnosis on a range of clinical pathways, including people with chronic respiratory disease.